{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:07Z","timestamp":1791499627797,"version":"4.3.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CBM"],"published-print":{"date-parts":[[2022,2,14]]},"abstract":"<jats:p>BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG), a live attenuated tuberculosis vaccine that acts as a non-specific immune system stimulant, is the most effective adjuvant treatment for patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC). However, to date, there are no reliable tests that are predictive of BCG treatment response. In this study, we evaluated the performance of OncuriaTM, a bladder cancer detection test, to predict response to intravesical BCG. METHODS: OncuriaTM data was evaluated in voided urine samples obtained from a prospectively collected cohort of 64 subjects with intermediate or high risk NMIBC prior to treatment with intravesical BCG. The OncuriaTM test, which measures 10 cancer-associated biomarkers was performed in an independent clinical laboratory. The ability of the test to identify those patients in whom BCG is ineffective against tumor recurrence was tested. Predictive models were derived using supervised learning and cross-validation analyses. Model performance was assessed using ROC curves. RESULTS: Pre-treatment urinary concentrations of MMP9, VEGFA, CA9, SDC1, PAI1, APOE, A1AT, ANG and MMP10 were increased in patients who developed disease recurrence. A combinatorial predictive model of treatment outcome achieved an AUROC 0.89 [95% CI: 0.80\u20130.99], outperforming any single biomarker, with a test sensitivity of 81.8% and a specificity of 84.9%. Hazard ratio analysis revealed that patients with higher urinary levels of ANG, CA9 and MMP10 had a significantly higher risk of disease recurrence. CONCLUSIONS: Monitoring the urinary levels of a cancer-associated biomarker panel enabled the discrimination of patients who did not respond to intravesical BCG therapy. With further study, the multiplex OncuriaTM test may be applicable for the clinical evaluation of bladder cancer patients considering intravesical BCG treatment.<\/jats:p>","DOI":"10.3233\/cbm-210221","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T11:08:28Z","timestamp":1631012908000},"page":"151-157","source":"Crossref","is-referenced-by-count":20,"title":["Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study"],"prefix":"10.1177","volume":"33","author":[{"given":"Kaoru","family":"Murakami","sequence":"first","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[{"name":"Department of Urology, UT MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pagano","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, HI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runpu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The State University of New York at Buffalo, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, The State University of New York at Buffalo, Buffalo, NY, USA"},{"name":"Department of Computer Science and Engineering, The State University of New York at Buffalo, Buffalo, NY, USA"},{"name":"Department of Biostatistics, The State University of New York at Buffalo, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Goodison","sequence":"additional","affiliation":[{"name":"Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Rosser","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA"},{"name":"Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA"},{"name":"Nonagen Bioscience Corp., Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Furuya","sequence":"additional","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/CBM-210221_ref1","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.3233\/CBM-210221_ref2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.3233\/CBM-210221_ref3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: A review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.3233\/CBM-210221_ref4","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: Implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"key":"10.3233\/CBM-210221_ref5","first-page":"244","article-title":"Bacille-Calmette-Guerin non-responders: How to manage","volume":"4","author":"von Rundstedt","year":"2015","journal-title":"Transl Androl Urol"},{"key":"10.3233\/CBM-210221_ref6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.urology.2007.10.041","article-title":"Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy","volume":"71","author":"Gupta","year":"2008","journal-title":"Urology"},{"key":"10.3233\/CBM-210221_ref7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10147-010-0049-6","article-title":"A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients","volume":"15","author":"Yamada","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"10.3233\/CBM-210221_ref8","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus Calmette-Guerin immunotherapy: Are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"key":"10.3233\/CBM-210221_ref9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","article-title":"Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation","volume":"34","author":"Lammers","year":"2016","journal-title":"World J Urol"},{"key":"10.3233\/CBM-210221_ref10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: A systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.3233\/CBM-210221_ref11","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-10-3121","article-title":"Urinary glycoprotein biomarker discovery for bladder cancer detection using LC\/MS-MS and label-free quantification","volume":"17","author":"Yang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.3233\/CBM-210221_ref12","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1021\/pr0700807","article-title":"Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling","volume":"6","author":"Kreunin","year":"2007","journal-title":"J Proteome Res"},{"key":"10.3233\/CBM-210221_ref13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/1055-9965.EPI-08-1002","article-title":"Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia","volume":"18","author":"Rosser","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.3233\/CBM-210221_ref14","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1055-9965.EPI-12-0428","article-title":"A candidate molecular biomarker panel for the detection of bladder cancer","volume":"21","author":"Urquidi","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.3233\/CBM-210221_ref15","doi-asserted-by":"crossref","unstructured":"H. Furuya, I. Pagano, K. Chee, T. Kobayashi, R.S. Wong, R. Lee and C.J. Rosser, Comparison of commercial ELISA kits, a prototype multiplex electrochemoluminescent assay, and a multiplex bead-based immunoassay for detecting a urine-based bladder-cancer-associated diagnostic signature, Diagnostics (Basel) 9 (2019).","DOI":"10.3390\/diagnostics9040166"},{"key":"10.3233\/CBM-210221_ref16","doi-asserted-by":"crossref","first-page":"e00189","DOI":"10.1016\/j.plabm.2020.e00189","article-title":"Analytical validation of ONCURIA a multiplex bead-based immunoassay for the non-invasive bladder cancer detection","volume":"22","author":"Furuya","year":"2020","journal-title":"Pract Lab Med"},{"key":"10.3233\/CBM-210221_ref17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12967-021-02796-4","article-title":"Diagnostic performance of Oncuria, a urinalysis test for bladder cancer","volume":"19","author":"Hirasawa","year":"2021","journal-title":"J Transl Med"},{"key":"10.3233\/CBM-210221_ref18","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.3233\/CBM-210221_ref19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Guerin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"10.3233\/CBM-210221_ref21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/bimj.200410135","article-title":"Estimation of the Youden Index and its associated cutoff point","volume":"47","author":"Fluss","year":"2005","journal-title":"Biom J"},{"key":"10.3233\/CBM-210221_ref22","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2307\/2533866","article-title":"Assessment of model adequacy for Markov regression time series models","volume":"54","author":"Leon","year":"1998","journal-title":"Biometrics"},{"key":"10.3233\/CBM-210221_ref23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1198\/0003130043277","article-title":"Bootstrap methods for developing predictive models","volume":"58","author":"Austin","year":"2004","journal-title":"The American Statistician"},{"key":"10.3233\/CBM-210221_ref24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guerin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.3233\/CBM-210221_ref25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1590\/S1677-55382009000600005","article-title":"UroVysion testing can lead to early identification of intravesical therapy failure in patients with high risk non-muscle invasive bladder cancer","volume":"35","author":"Whitson","year":"2009","journal-title":"Int Braz J Urol"},{"key":"10.3233\/CBM-210221_ref26","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1002\/ijc.24258","article-title":"The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy","volume":"124","author":"Savic","year":"2009","journal-title":"Int J Cancer"},{"key":"10.3233\/CBM-210221_ref27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/JU.0000000000000355","article-title":"Evaluation of the fluorescence in situ hybridization test to predict recurrence and\/or progression of disease after bacillus Calmette-Guerin for primary high grade nonmuscle invasive bladder cancer: Results from a prospective multicenter trial","volume":"202","author":"Lotan","year":"2019","journal-title":"J Urol"},{"key":"10.3233\/CBM-210221_ref28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"10.3233\/CBM-210221_ref29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1126\/science.2432664","article-title":"Angiogenic factors","volume":"235","author":"Folkman","year":"1987","journal-title":"Science"},{"key":"10.3233\/CBM-210221_ref30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.3233\/CBM-210221_ref31","first-page":"89","article-title":"Tumor interactions with the vasculature: Angiogenesis and tumor metastasis","volume":"1032","author":"Blood","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/CBM-210221_ref32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/1541-7786.MCR-13-0543","article-title":"PAI-1 leads to G1-phase cell-cycle progression through cyclin D3\/cdk4\/6 upregulation","volume":"12","author":"Giacoia","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.3233\/CBM-210221_ref33","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/onc.2014.2","article-title":"Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1\/2 pathway","volume":"34","author":"Miyake","year":"2015","journal-title":"Oncogene"},{"key":"10.3233\/CBM-210221_ref34","first-page":"997","article-title":"Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation","volume":"34","author":"Liotta","year":"1974","journal-title":"Cancer Res"},{"key":"10.3233\/CBM-210221_ref35","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/jnci\/84.24.1875","article-title":"Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma","volume":"84","author":"Weidner","year":"1992","journal-title":"J Natl Cancer Inst"}],"container-title":["Cancer Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/CBM-210221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:08:26Z","timestamp":1777385306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/CBM-210221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":34,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/cbm-210221","relation":{},"ISSN":["1875-8592","1574-0153"],"issn-type":[{"value":"1875-8592","type":"electronic"},{"value":"1574-0153","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}